Loss of mitogen‐activated protein kinase phosphate‐5 aggravates islet dysfunction in mice with type 1 and type 2 diabetes

Abstract

AbstractImpaired functionality and loss of islet β‐cells are the primary abnormalities underlying the pathogenesis of both type 1 and 2 diabetes (T1DM and T2DM). However, specific therapeutic and preventive mechanisms underlying these conditions remain unclear. Mitogen‐activated protein kinase phosphatase‐5 (MKP‐5) has been implicated in carcinogenesis, lipid metabolism regulation, and immune cell activation. In a previous study, we demonstrated the involvement of exogenous MKP‐5 in the regulation of obesity‐induced T2DM. However, the role of endogenous MKP‐5 in the T1DM and T2DM processes is unclear. Thus, mice with MKP‐5 knockout (KO) were generated and used to establish mouse models of both T1DM and T2DM. Our results showed that MKP‐5 KO exacerbated diabetes‐related symptoms in mice with both T1DM and T2DM. Given that most phenotypic studies on islet dysfunction have focused on mice with T2DM rather than T1DM, we specifically aimed to investigate the role of endoplasmic reticulum stress (ERS) and autophagy in T2DM KO islets. To accomplish this, we performed RNA sequence analysis to gain comprehensive insight into the molecular mechanisms associated with ERS and autophagy in T2DM KO islets. The results showed that the islets from mice with MKP‐5 KO triggered 5′ adenosine monophosphate‐activated protein kinase (AMPK)‐mediated autophagy inhibition and glucose‐regulated protein 78 (GRP‐78)‐dominated ERS. Hence, we concluded that the autophagy impairment, resulting in islet dysfunction in mice with MKP‐5 KO, is mediated through GRP‐78 involvement. These findings provide valuable insights into the molecular pathogenesis of diabetes and highlight the significant role of MKP‐5. Moreover, this knowledge holds promise for novel therapeutic strategies targeting MKP‐5 for diabetes management.